Getting a cancer diagnosis can be difficult, but having the right support group matters, and if that support group also ...

Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to ...

Two recent studies from Dr. Sita Kugel’s lab at Fred Hutch Cancer Center identify a key biological signature that not only ...

IL-6 blockades with tocilizumab did not improve short-term survival in advanced pancreatic cancer but showed potential ...

Urgent pancreatic cancer tests will be offered on the NHS for those who are most at risk. GPs taking part in the NHS pilot ...

Pancreatic cancer has a five-year survival rate of just 13%, making it the deadliest cancer, according to the American Cancer ...

New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in ...

Around half of people diagnosed with pancreatic cancer will have been diagnosed with diabetes recently, according to NHS ...

OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel ...

Atebimetinib combined with modified chemotherapy achieved a 94% six-month overall survival rate in first-line pancreatic cancer patients, surpassing the typical 67% with standard treatment. The ...

Getting a cancer diagnosis can be difficult, but having the right support group matters, and if that support group also happens to be in healthcare, all the better.